State Street SPDR S&P Pharmaceuticals ETF
XPH
77 hedge funds and large institutions have $107M invested in State Street SPDR S&P Pharmaceuticals ETF in 2021 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 23 increasing their positions, 17 reducing their positions, and 13 closing their positions.
35% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 17
23% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 13
6% more capital invested
Capital invested by funds: $101M → $107M (+$5.64M)
3.67% more ownership
Funds ownership: 43.47% → 47.14% (+3.7%)
1% less funds holding
Funds holding: 78 → 77 (-1)
48% less call options, than puts
Call options by funds: $452K | Put options by funds: $872K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$6.36M |
| 2 |
CF
Centaurus Financial
Anaheim,
California
|
+$2.7M |
| 3 |
MCM
MAI Capital Management
Independence,
Ohio
|
+$2.49M |
| 4 |
FIM
FWL Investment Management
Dallas,
Texas
|
+$1.72M |
| 5 |
TAM
Tocqueville Asset Management
New York
|
+$1.63M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BNP Paribas Financial Markets
Paris,
France
|
-$4.74M |
| 2 |
Goldman Sachs
New York
|
-$2.33M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$1.64M |
| 4 |
IMC Chicago
Chicago,
Illinois
|
-$527K |
| 5 |
FTUS
Flow Traders U.S.
New York
|
-$378K |
XPH Hedge Fund Activity: Q4 2021 in Review
77 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Pharmaceuticals ETF (XPH) for Q4 2021, worth a combined $107M — up 5.6% from $101M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new XPH positions and 13 closed out — a net gain of 3 holders — while 23 added to existing stakes and 17 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $6.36M. The largest seller was BNP Paribas Financial Markets, cutting an estimated $4.74M.
- 77 institutional investors held State Street SPDR S&P Pharmaceuticals ETF (XPH) as of Q4 2021, down from 78 in Q3 2021.
- Funds reported $107M of State Street SPDR S&P Pharmaceuticals ETF stock for Q4 2021, up 5.6% quarter-over-quarter.
- 16 funds opened new State Street SPDR S&P Pharmaceuticals ETF positions in Q4 2021 and 13 closed out, a net change of +3 holders.
- The largest State Street SPDR S&P Pharmaceuticals ETF buyer in Q4 2021 was Morgan Stanley, an estimated $6.36M added.
- The largest State Street SPDR S&P Pharmaceuticals ETF seller in Q4 2021 was BNP Paribas Financial Markets, an estimated $4.74M sold.
Based on aggregated 13F filings for Q4 2021.